Literature DB >> 2939246

Etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid): a potent antiinflammatory drug. Conformation and absolute configuration of its active enantiomer.

L G Humber, C A Demerson, P Swaminathan, P H Bird.   

Abstract

The active (+) enantiomer of the antiinflammatory agent etodolac (1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid) has been assigned an S absolute configuration on the basis of a crystallographic analysis of the (S)-(-)-borneol ester of (-)-etodolac, and the conformation of etodolac has been determined by a crystallographic analysis of (+/-)-etodolac. Analyses of the solid-state conformation, as well as energy-minimized conformations obtained by molecular mechanics calculations, have failed to provide a basis for identifying a probable receptor-site conformation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939246     DOI: 10.1021/jm00155a047

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs.

Authors:  F Jamali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Jan-Mar       Impact factor: 2.441

2.  Development of an Enantioselective and Biomarker-Informed Translational Population Pharmacokinetic/Pharmacodynamic Model for Etodolac.

Authors:  Carolina de Miranda Silva; Adriana Rocha; Eduardo Tozatto; Lucienir Maria da Silva; Eduardo Antônio Donadi; Teresa Dalla Costa; Vera Lucia Lanchote; Stephan Schmidt; Jürgen B Bulitta
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

3.  SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Authors:  Hiroshi Yasui; Teru Hideshima; Makoto Hamasaki; Aldo M Roccaro; Norihiko Shiraishi; Shaji Kumar; Pierfrancesco Tassone; Kenji Ishitsuka; Noopur Raje; Yu-Tzu Tai; Klaus Podar; Dharminder Chauhan; Lorenzo M Leoni; Sarath Kanekal; Gary Elliott; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

Review 4.  Etodolac clinical pharmacokinetics.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

5.  An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.

Authors:  Marcus Baumann; Ian R Baxendale; Steven V Ley; Nikzad Nikbin
Journal:  Beilstein J Org Chem       Date:  2011-04-18       Impact factor: 2.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.